Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21762128 | 0.83 | LMNA (0.41) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10141246 | 0.82 | LMNA (0.49) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17108555 | 0.81 | LMNA (0.40) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2760656 | 0.81 | ADRB2 (0.43) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL31251933 | 0.81 | LMNA (0.40) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL961068 | 0.81 | LMNA (0.40) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17154813 | 0.81 | LMNA (0.40) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL594622 | 0.81 | ADRB2 (0.43) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4356472 | 0.81 | LMNA (0.40) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL956785 | 0.81 | ADRB2 (0.43) | LMNAMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328126-B2 | Norbornenylhydrocarbylene dihydrocarbylboranes and methods of making the same | PROMERUS, LLC (US) | 2016-05-03 | — | — | US | claimed |
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2015-12-10 | — | — | US | claimed |
| WO-2014121008-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2014-08-07 | — | — | WO | claimed |
| US-8106200-B2 | Pyridine borane complexes | BASF SE (DE) | 2012-01-31 | — | — | US | claimed |
| US-20110207934-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2011-08-25 | — | — | US | claimed |
| EP-2066631-B1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2011-04-06 | — | — | EP | claimed |
| CN-101516846-A | Pyridine borane complexes | BASF AG (DE) | 2009-08-26 | — | — | CN | claimed |
| EP-2066631-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008034886-A1 | PYRIDINE BORANE COMPLEXES | BASF SE (DE) | 2008-03-27 | — | — | WO | claimed |
| EP-0015763-B1 | ZIEGLER TYPE CATALYST SYSTEM | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1984-05-16 | — | — | EP | claimed |
| US-4374051-A | ISOPROPENYL- OR ACETYL SUBSTITUTED PYRIDINE DERIVATIVES; REGENERATION OF ESSENTIAL OILS; FLAVORS | FIRMENICH SA (CH) | 1983-02-15 | — | — | US | claimed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-0039842-A1 | Improvements in or relating to smoking compositions | PHILIP MORRIS INCORPORATED (US) | 1981-11-18 | — | — | EP | disclosed |
| EP-0037163-A2 | Flavouring agents, smoking compositions, combustible articles and foodstuffs containing such agents, and a method of producing the same | PHILIP MORRIS INCORPORATED (US) | 1981-10-07 | — | — | EP | disclosed |
| US-4259969-A | HYDROXYALKYLPYRAZINES AND -PYRIDINES | PHILIP MORRIS INCORPORATED (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0021663-A1 | A polyheterocyclic compound, its preparation and a smoking composition in which it is used | PHILIP MORRIS INCORPORATED (US) | 1981-01-07 | — | — | EP | disclosed |
| EP-0015073-A1 | Smoking, flavored and foodstuff compositions | PHILIP MORRIS INCORPORATED (US) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | CYP8B1, BDKRB1, CYP1B1 | LMNA 449/4885MEN1 116/4885KMT2A 2288/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | LMNA 1340/4885MEN1 4363/4885KMT2A 3434/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | LMNA 776/4885MEN1 3551/4885KMT2A 97/4885 |
| US-20110207934-A1 | PYRIDINE BORANE COMPLEXES | NBAS, BRD8, PAXBP1 | LMNA 3308/4885MEN1 1142/4885KMT2A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.